Dr. Rini Explains the Axitinib Integration Process

Brian I. Rini, MD
Published: Monday, Jul 11, 2011

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio discusses the integration of axitinib into the clinical practice, initially, he believes, in the refractory setting and soon in the front-line as new trial results come in, the most recent trial completed was the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC) which found axitinib to be superior to sorafenib.
Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio discusses the integration of axitinib into the clinical practice, initially, he believes, in the refractory setting and soon in the front-line as new trial results come in, the most recent trial completed was the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC) which found axitinib to be superior to sorafenib.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x